{"product_id":"respiratory-disease-in-the-covid-19-masaki-okamoto-9783036579160","title":"Respiratory Disease in the COVID-19 Era","description":"\u003cp\u003eCoronavirus disease 2019 (COVID-19) is a new respiratory disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that caused a global pandemic. COVID-19 patients often develop acute respiratory distress syndrome (ARDS), which involves acute and lethal respiratory failure. In a meta-analysis, the median incidence of ARDS in COVID-19 patients was found to be 35 (2-79)%, while the mortality rate in COVID-19-associated ARDS patients was found to be 39 (12.5-73.1)% (Hasan, et al. \u003cem\u003eExpert Rev Repoir Med.\u003c\/em\u003e 2020; 14: 1149). As of 12 December 2021, 270,373,764 cases had been confirmed as COVID-19 and 5,321,321 cases had resulted in death, according to the World Health Organization webpage. Various symptoms such as persistent fatigue, myalgia, and insomnia can persist after recovery from COVID-19; these symptoms are called \"long COVID-19\". Patients with COVID-19 who survive but develop pulmonary fibrosis may experience persistent dyspnea upon exertion, a decrease in pulmonary function, and\/or a radiological abnormal shadow. Antifibrotic drugs including nintedanib and pirfenidone are candidate drugs for the treatment of pulmonary fibrosis due to COVID-19; randomized controlled trials are ongoing.\u003c\/p\u003e\u003cp\u003eHowever, there are limited studies about respiratory disease caused by COVID-19. Given the clinical significance of this topic and its impact on clinical practice and public health, Medicina have published a Special Issue entitled \"Respiratory Disease in the COVID-19 Era\" with the aim of gathering accurate and up-to-date scientific information of this topic.\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eAuthor:\u003c\/b\u003e Masaki Okamoto\u003cbr\u003e\u003cb\u003eISBN-10:\u003c\/b\u003e 3036579168\u003cbr\u003e\u003cb\u003eISBN-13:\u003c\/b\u003e 9783036579160\u003cbr\u003e\u003cb\u003ePublisher:\u003c\/b\u003e Mdpi AG\u003cbr\u003e\u003cb\u003eLanguage:\u003c\/b\u003e English\u003cbr\u003e\u003cb\u003ePublished:\u003c\/b\u003e 06\/14\/2023\u003cbr\u003e\u003cb\u003ePages:\u003c\/b\u003e 112\u003cbr\u003e\u003cb\u003eFormat:\u003c\/b\u003e Hardcover\u003cbr\u003e\u003cb\u003eWeight:\u003c\/b\u003e 0.98lbs\u003cbr\u003e\u003cb\u003eSize:\u003c\/b\u003e 9.61h x 6.69w x 0.44d","brand":"Masaki Okamoto","offers":[{"title":"Hardcover","offer_id":48113798217983,"sku":"9783036579160","price":61.01,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/2982\/9887\/files\/img_c5d94ec5-338f-4b78-9090-553846bd0636.jpg?v=1769617367","url":"https:\/\/www.whiterainbookhouse.com\/products\/respiratory-disease-in-the-covid-19-masaki-okamoto-9783036579160","provider":"WR Book House","version":"1.0","type":"link"}